David Roth
About
Research
Publications
2024
A Case of Pediatric Steroid-Resistant FSGS Evolving into a Steroid-Sensitive Profile in Young Adulthood
Fontanella A, Grewal M, Serrano V, Burke G, Fornoni A, Roth D. A Case of Pediatric Steroid-Resistant FSGS Evolving into a Steroid-Sensitive Profile in Young Adulthood. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.20243tp0p1w3. DOI: 10.1681/asn.20243tp0p1w3.Peer-Reviewed Original ResearchPreemptive Kidney Transplantation Trends in Lupus
Contreras G, Pagan J, Elfassy T, Bandes M, Bustamante N, Goggins M, Becerra L, Mendoza J, Drexler Y, Alonso S, Roth D. Preemptive Kidney Transplantation Trends in Lupus. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024p18r0q9c. DOI: 10.1681/asn.2024p18r0q9c.Peer-Reviewed Original ResearchEfficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Chatham W, Clark K, Furie R, Groark J, Urowitz M, van Vollenhoven R, Daniels M, Fox N, Gregan Y, Henderson R, van Maurik A, Ocran-Appiah J, Oldham M, Roth D, Shanahan D, Tak P, Teng Y. Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study. Annals Of The Rheumatic Diseases 2024, 83: ard-2024-225686. PMID: 39159997, PMCID: PMC11503042, DOI: 10.1136/ard-2024-225686.Peer-Reviewed Original ResearchSystemic lupus erythematosusProportion of patientsCycles of rituximabSubcutaneous belimumabLupus erythematosusSafety of sequential therapyModified intention-to-treat populationIntention-to-treat populationDisease control durationDisease controlInvestigation of combination treatmentsDisease activity markersAnti-dsDNA antibodiesDisease activity controlIntravenous placeboImmunosuppression withdrawalIntravenous rituximabSequential therapyClinical remissionStandard therapySecondary endpointsActivation markersAnti-dsDNARituximabPhase 3Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Arends E, Zlei M, Tipton C, Cotic J, Osmani Z, de Bie F, Kamerling S, van Maurik A, Dimelow R, Gregan Y, Fox N, Rabelink T, Roth D, Sanz I, van Dongen J, van Kooten C, Teng Y. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology 2024, 63: 2387-2398. PMID: 38775637, PMCID: PMC11371378, DOI: 10.1093/rheumatology/keae286.Peer-Reviewed Original ResearchMemory B cellsSystemic lupus erythematosusCirculating memory B cellsB cellsLupus nephritisLupus erythematosusAutoreactive memory B cellsMemory B cell subsetsSLE disease activityMemory B cell phenotypeEfficacy of belimumabSerologically active patientsHigh-sensitivity flow cytometryNaive B cellsB-cell traffickingB cell activationInhibition of B cell activationRetrospective meta-analysisBelimumab initiationIntravenous belimumabSubcutaneous belimumabBelimumabDisease activityLymphocyte traffickingAutoimmune diseasesWCN24-330 TRENDS OF PREEMPTIVE KIDNEY TRANSPLANTATION IN PATIENTS APPROACHING END-STAGE RENAL DISEASE STRATIFIED BY PRIMARY DISEASE IN THE UNITED STATES FROM 1985 AND 2019
Martin G, Pagan J, Bustamante N, Ortigosa-Goggins M, Bandes M, Elfassy T, Becerra L, Mendoza J, Morales E, Drexler Y, Kupin W, Roth D. WCN24-330 TRENDS OF PREEMPTIVE KIDNEY TRANSPLANTATION IN PATIENTS APPROACHING END-STAGE RENAL DISEASE STRATIFIED BY PRIMARY DISEASE IN THE UNITED STATES FROM 1985 AND 2019. Kidney International Reports 2024, 9: s442-s443. DOI: 10.1016/j.ekir.2024.02.929.Peer-Reviewed Original ResearchTransplantation: platform to study recurrence of disease
Burke G, Mitrofanova A, Fontanella A, Vendrame F, Ciancio G, Vianna R, Roth D, Ruiz P, Abitbol C, Chandar J, Merscher S, Pugliese A, Fornoni A. Transplantation: platform to study recurrence of disease. Frontiers In Immunology 2024, 15: 1354101. PMID: 38495894, PMCID: PMC10940352, DOI: 10.3389/fimmu.2024.1354101.Peer-Reviewed Original Research
2023
Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN)
Rovin B, Furie R, Malvar A, Aranow C, Pego-Reigosa J, Zakharova E, Schwarting A, Jones-Leone A, Gilbride J, Ji B, Roth D, Curtis P, van Maurik A. Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN). Journal Of The American Society Of Nephrology 2023, 34: 972-973. DOI: 10.1681/asn.20233411s1972c.Peer-Reviewed Original Research
2021
Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)
Anders H, Rovin B, Zhao M, Malvar A, Hiromura K, Jones-Leone A, González-Rivera T, Gilbride J, Madan A, Green Y, Roth D. Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN). Journal Of The American Society Of Nephrology 2021, 32: 48-49. DOI: 10.1681/asn.20213210s148c.Peer-Reviewed Original Research
2020
Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial
Rovin B, Houssiau F, Furie R, Malvar A, Teng Y, Mok C, Contreras G, Yu X, Dolff S, Ji B, Roth D, Kleoudis C, Makowiak S, Madan A, Gilbride J, Green Y. Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial. Journal Of The American Society Of Nephrology 2020, 31: 54-54. DOI: 10.1681/asn.20203110s154a.Peer-Reviewed Original Research
2013
OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations
Schmitt C, Roth D, Birch H, Kleoudis C, De Vries J. OP0115 Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Disease Activity in Key Organ Systems: Bliss Sub-Populations. Annals Of The Rheumatic Diseases 2013, 72: a90. DOI: 10.1136/annrheumdis-2013-eular.320.Peer-Reviewed Original ResearchSF-36 physical component scoreEfficacy of belimumabPhysician global assessmentHigh disease activityPhysical component scoreSLE patientsSELENA-SLEDAIDisease activityMean physician’s global assessmentSystemic lupus erythematosus patientsSF-36Treating SLE patientsDisease activity groupLupus erythematosus patientsSLE Responder IndexWeeks of treatmentDisease activity criteriaBelimumab doseFACIT-Fatigue scoresLow complementDouble-blindPlus standard carePrimary endpointSecondary endpointsDisease flare